ClinicalTrials.gg
RecruitingNCT07852403PAH-SDBUpdated Oct 1, 2026

PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension

An observational study in Pulmonary Arterial Hypertension (PAH) and Sleep-disordered Breathing (SDB), sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.

Planned enrollment
6th of 20
1,500 · median 495
Started
2026
with 2 others
Observational
20 of 76
10 open now
Primary completion
2031-12
later than 23 of 23 live
Registered
76th of 76
by date
Lead sponsor
4 of 76
Chinese Pulmonary Vascular Disease Research Group

Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 6th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2026, is one of 20 observational ones, reaches primary completion later than 23 of the 23 other live ones, and was the 76th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Pulmonary Arterial Hypertension with a site in China, or all of them as a file.
02

Study summary

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality. Sleep-disordered breathing (SDB) and sleep-related hypoxemia are common in patients with PAH, but their prevalence, physiological determinants, longitudinal trajectories, prognostic significance, and potential role in individualized management remain incompletely defined.

PAH-SDB is a prospective, multicenter, observational patient registry enrolling adults with right-heart-catheterization-confirmed World Health Organization Group 1 PAH at pulmonary vascular centers across China. Participants will undergo standardized nocturnal sleep and cardiorespiratory monitoring together with comprehensive PAH assessment, including clinical characteristics, functional status, biomarkers, echocardiography, hemodynamics, treatment, and outcomes. Selected participants may undergo additional polysomnography, cardiac magnetic resonance imaging, wearable monitoring, repeated sleep assessments, or biospecimen collection when available and ethically approved.

The registry will characterize the prevalence and phenotypes of sleep-disordered breathing and nocturnal physiological abnormalities; examine their relationships with PAH severity and right ventricular-pulmonary vascular function; determine their value for predicting clinical worsening, hospitalization, transplantation, and mortality; evaluate longitudinal changes in sleep physiology in relation to PAH treatment and disease trajectory; and develop and validate multimodal statistical and artificial-intelligence models for phenotyping, risk prediction, and treatment-response stratification. Clinical management will remain at the discretion of treating physicians, and the registry will not assign PAH or sleep-related therapies.

Read the detailed description

PAH-SDB is designed as a disease-based prospective multicenter patient registry and longitudinal cohort. The registry addresses the interaction between sleep-disordered breathing (SDB) or nocturnal respiratory physiology and pulmonary vascular disease across the contemporary treatment era of pulmonary arterial hypertension (PAH). The study is intentionally broader than an apnea-hypopnea-index-centered cohort and will capture obstructive and central respiratory events, sustained and intermittent hypoxemia, desaturation morphology and burden, heart-rate and autonomic responses, respiratory instability, sleep fragmentation when available, and other digital physiological features derived from validated sleep or wearable devices.

Eligible participants will have WHO Group 1 PAH confirmed by right heart catheterization using contemporary hemodynamic criteria. Baseline assessment will include PAH etiology and duration, comorbidities, symptoms and WHO functional class, six-minute walk distance, natriuretic peptides and routine laboratory tests, electrocardiography, echocardiography, right-heart-catheterization variables, PAH-specific therapies, oxygen and positive-airway-pressure use, patient-reported outcomes where feasible, and a standardized overnight sleep study. The core sleep protocol will include airflow, respiratory effort, pulse oximetry, heart rate or electrocardiographic information, body position, and snoring when supported by the device. Full polysomnography will be performed in a nested subgroup according to clinical indication, center capability, or dedicated substudy protocols.

Participants will be followed longitudinally for clinical worsening, PAH-related hospitalization, therapy escalation, lung or heart-lung transplantation, and mortality. Repeated PAH assessments will be obtained according to routine clinical care, with harmonized registry time points. Repeat sleep monitoring is planned in a longitudinal subset, particularly after major changes in PAH treatment, clinically meaningful change in disease status, or initiation of sleep-related therapy. The registry will therefore support both baseline phenotype-outcome analyses and analyses of dynamic change.

Major scientific objectives are: (1) to determine the prevalence and distribution of sleep-disordered breathing and nocturnal hypoxemia in contemporary Chinese PAH; (2) to identify demographic, clinical, hemodynamic, imaging, and treatment correlates of nocturnal physiological phenotypes; (3) to quantify associations between sleep metrics and PAH severity, right ventricular structure and function, and validated risk strata; (4) to determine the incremental prognostic value of nocturnal physiological markers beyond established PAH risk tools; (5) to evaluate whether changes in sleep physiology track or precede changes in PAH status and treatment response; (6) to explore heterogeneity of associations across PAH subtypes, sex, age, body mass index, comorbidity burden, and treatment patterns; and (7) to develop and externally validate multimodal machine-learning and artificial-intelligence models for physiological endotyping, risk prediction, and individualized clinical decision support.

Registry quality procedures will include a standardized electronic case-report form, a data dictionary, investigator training, site initiation procedures, automated range and consistency checks, centralized data queries, periodic completeness reports, prespecified sleep-signal quality criteria, central or centrally supervised sleep scoring for key analyses, and adjudication of major clinical worsening events. A statistical analysis plan will be finalized before primary analyses. Conventional regression and time-to-event methods will be complemented by longitudinal mixed-effects models, internal-external validation across sites, causal-inference approaches for treatment-response analyses when appropriate, and multimodal machine-learning methods. Missing data mechanisms will be documented and addressed using prespecified statistical methods.

The registry is non-interventional. PAH therapy, oxygen therapy, positive airway pressure, and other clinical management will be prescribed by treating clinicians according to clinical judgment and prevailing guidelines. Any future substudy that prospectively assigns an intervention will be governed by a separate protocol and registered separately when required.

03

Conditions studied

  • Pulmonary Arterial Hypertension (PAH)
  • Sleep-disordered Breathing (SDB)

Keywords

  • Pulmonary arterial hypertension
  • sleep apnea
  • obstructive sleep apnea
  • central sleep apnea
  • nocturnal hypoxemia
  • hypoxic burden
  • oxygen desaturation
  • right ventricular function
  • right heart catheterization
  • risk stratification
  • clinical worsening
  • real-world evidence
  • digital biomarkers
  • wearable devices
  • artificial intelligence
  • machine learning
  • precision medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive adult patients with RHC-confirmed WHO Group 1 PAH receiving care at participating pulmonary vascular and cardiovascular centers in China. The registry will include newly diagnosed and prevalent PAH, with enrollment strata defined by disease duration and treatment status. Participating centers will include Fuwai Hospital and additional Chinese centers with expertise in PAH and the ability to perform standardized clinical and nocturnal physiological assessments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at enrollment.
  • Diagnosis of WHO Group 1 pulmonary arterial hypertension established by right heart catheterization using contemporary hemodynamic criteria: mean pulmonary artery pressure >20 mmHg at rest, pulmonary arterial wedge pressure ≤15 mmHg, and pulmonary vascular resistance >2 Wood units, with clinical classification consistent with Group 1 PAH.
  • PAH etiology may include idiopathic, heritable, drug/toxin-associated, connective-tissue-disease-associated, congenital-heart-disease-associated PAH after appropriate clinical classification, portal-hypertension-associated PAH, -associated PAH, or other recognized Group 1 PAH subtypes.
  • Clinically stable enough to undergo overnight sleep/cardiorespiratory monitoring, as judged by the treating team.
  • Able and willing to provide written and participate in longitudinal follow-up.
  • Enrollment at a participating center with availability of the required baseline PAH dataset and a technically interpretable protocol-standardized sleep recording.

Exclusion criteria

Exclusion Criteria:

  • Pulmonary hypertension predominantly attributable to left heart disease (Group 2), lung disease and/or hypoxia (Group 3), chronic thromboembolic pulmonary hypertension or other pulmonary artery obstruction (Group 4), or unclear/multifactorial mechanisms (Group 5).
  • Pulmonary veno-occlusive disease / pulmonary capillary hemangiomatosis when the clinical phenotype is considered separately from conventional PAH for the planned analysis, unless the protocol intentionally includes this subgroup and prespecifies it as a distinct stratum.
  • Acute decompensated right heart failure, cardiogenic shock, severe active infection, or another acute condition that would make the baseline sleep recording unrepresentative or unsafe; these patients may be reconsidered after stabilization.
  • Current hospitalization primarily for an acute non-PAH illness likely to substantially distort nocturnal respiratory physiology.
  • Inability to obtain an adequate baseline sleep/cardiorespiratory recording after protocol-defined repeat attempt, unless the participant is retained in a registry-only stratum for non-sleep analyses.
  • Inability to provide or anticipated inability to complete meaningful follow-up.
  • Any other condition that, in the investigator's judgment, would prevent reliable study participation or data interpretation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • PAH-SDB Prospective Cohort

    Adults with right-heart catheterization (RHC)-confirmed WHO Group 1 pulmonary arterial hypertension (PAH) consecutively enrolled at participating Chinese centers and followed prospectively with standardized nocturnal sleep/cardiorespiratory phenotyping and longitudinal PAH assessments.

    Diagnostic Test: Standardized Overnight Sleep and Cardiorespiratory Monitoring

Interventions

  • Diagnostic testStandardized Overnight Sleep and Cardiorespiratory Monitoring

    Participants undergo protocol-standardized nocturnal monitoring without study-assigned therapy. The core recording includes airflow, respiratory effort, oxygen saturation, pulse/heart rate, body position, and snoring when available. Full polysomnography, extended wearable monitoring, repeated sleep studies, and other physiological signals may be obtained in nested subcohorts. All sleep-related treatment decisions remain under routine clinical care.

06

What researchers measure

Primary outcomes

  1. Prevalence and phenotypic distribution of sleep-disordered breathing and nocturnal hypoxemia

    Proportion of participants with sleep-disordered breathing (SDB) and its phenotypes, including obstructive sleep apnea (OSA) and central sleep apnea (CSA), together with the distribution of nocturnal hypoxemia and multidimensional sleep physiological burden. Core measures will include the apnea-hypopnea index (AHI) or respiratory event index (REI), obstructive and central respiratory event indices, oxygen desaturation index (ODI), percentage of recording time with peripheral oxygen saturation below 90% (T90), mean and minimum peripheral oxygen saturation (SpO₂), and prespecified hypoxic-burden metrics. Prevalence estimates will be reported with 95% confidence intervals.

    Time frame: Baseline

  2. Time to first clinical worsening event

    Time from enrollment to the first adjudicated clinical worsening event. The primary composite is recommended to include all-cause death, lung or heart-lung transplantation, PAH-related unplanned hospitalization, atrial septostomy, or clinically driven major PAH treatment escalation/rescue therapy because of documented disease worsening. A sensitivity definition limited to hard outcomes will also be analyzed.

    Time frame: From enrollment through 5 years of follow-up

Secondary outcomes

  1. All-cause mortality

    Time from enrollment to death from any cause

    Time frame: From enrollment through 5 years of follow-up

  2. Transplant-free survival

    Time to death or lung/heart-lung transplantation

    Time frame: From enrollment through 5 years of follow-up

  3. PAH-related hospitalization

    Time to first PAH-related unplanned hospitalization and recurrent hospitalization burden

    Time frame: From enrollment through 5 years of follow-up

  4. Change From Baseline in REVEAL 2.0 Risk Score

    The REVEAL 2.0 risk score will be calculated using available clinical variables according to the established REVEAL 2.0 algorithm. Higher scores indicate greater predicted mortality risk. Change from baseline will be evaluated at available follow-up assessments.

    Time frame: Baseline to longitudinal follow-up through 5 years

  5. Change From Baseline in ESC/ERS Four-Strata Risk Status

    PAH risk status will be assessed using the ESC/ERS four-strata risk assessment approach and classified as low risk, intermediate-low risk, intermediate-high risk, or high risk. For longitudinal analyses, the four categories will be coded ordinally from 1 to 4, with higher values indicating greater estimated risk. Changes from baseline will be assessed during follow-up.

    Time frame: Baseline to longitudinal follow-up through 5 years

  6. Change From Baseline in WHO Functional Class

    WHO functional class will be assessed according to the World Health Organization functional classification for pulmonary hypertension, ranging from Class I to Class IV. A higher class indicates greater functional limitation.

    Time frame: Baseline to 3-6 months, 12 months, and annual follow-up through 5 years.

  7. Change From Baseline in 6-Minute Walk Distance

    Exercise capacity will be assessed using the 6-minute walk distance performed according to standardized clinical procedures. Change from baseline in walking distance will be evaluated during follow-up.

    Time frame: Baseline to 3-6 months, 12 months, and annual follow-up through 5 years.

  8. Change From Baseline in N-Terminal Pro-B-Type Natriuretic Peptide

    Plasma N-terminal pro-B-type natriuretic peptide concentration will be recorded when measured as part of routine clinical assessment. Change from baseline will be evaluated at available follow-up assessments.

    Time frame: Baseline to 3-6 months, 12 months, and annual follow-up through 5 years.

  9. Change From Baseline in Right Atrial Pressure

    Right atrial pressure will be measured by right-heart catheterization. Longitudinal change will be evaluated in participants who undergo clinically indicated repeat right-heart catheterization.

    Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years

  10. Change From Baseline in Mean Pulmonary Artery Pressure

    Mean pulmonary artery pressure will be measured by right-heart catheterization. Longitudinal change will be evaluated when repeat right-heart catheterization data are available.

    Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years

  11. Change From Baseline in Pulmonary Arterial Wedge Pressure

    Pulmonary arterial wedge pressure will be measured during right-heart catheterization.

    Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years

  12. Change From Baseline in Cardiac Index

    Cardiac output will be determined during right-heart catheterization according to the standardized method used at the participating center. Cardiac index will be calculated as cardiac output indexed to body surface area.

    Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years

  13. Change From Baseline in Pulmonary Vascular Resistance

    Pulmonary vascular resistance will be calculated from invasive hemodynamic measurements obtained during right-heart catheterization.

    Time frame: Baseline to repeat right-heart catheterization during follow-up, up to 5 years

  14. Change From Baseline in Respiratory Event Index

    Respiratory event index will be calculated as the number of scored respiratory events per hour of valid recording time in participants assessed using portable cardiorespiratory monitoring.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  15. Change From Baseline in Apnea-Hypopnea Index

    Apnea-hypopnea index will be calculated as the number of apneas and hypopneas per hour of total sleep time in participants undergoing polysomnography.

    Time frame: Baseline to repeat polysomnography during follow-up, up to 5 years

  16. Change From Baseline in Oxygen Desaturation Index

    Oxygen desaturation index will be calculated as the number of qualifying oxygen desaturation events per hour of valid recording time according to the prespecified scoring criteria.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  17. Change From Baseline in Percentage of Recording Time With Oxygen Saturation Below 90% (T90)

    T90 will be defined as the percentage of valid overnight recording time during which peripheral oxygen saturation is below 90%.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  18. Change From Baseline in Mean Overnight Oxygen Saturation

    Mean peripheral oxygen saturation will be calculated across the valid overnight recording period.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  19. Change From Baseline in Minimum Overnight Oxygen Saturation

    Minimum peripheral oxygen saturation will be defined as the lowest valid oxygen saturation value recorded during the overnight monitoring period after signal-quality control.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  20. Change From Baseline in Respiratory Event-Associated Hypoxic Burden

    Respiratory event-associated hypoxic burden will quantify the cumulative area under oxygen desaturation curves associated with scored respiratory events, normalized by recording duration.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  21. Change From Baseline in Mean Event-Related Heart-Rate Surge

    Event-related heart-rate surge will be calculated as the increase from the pre-event heart-rate baseline to the post-event peak heart rate for each qualifying respiratory event. The participant-level mean event-related heart-rate surge will be used for longitudinal analysis.

    Time frame: Baseline to repeat sleep monitoring during follow-up, up to 5 years

  22. Change From Baseline in Tricuspid Annular Plane Systolic Excursion

    Tricuspid annular plane systolic excursion (TAPSE) will be measured by echocardiography as an index of right ventricular longitudinal systolic function. Change from baseline will be evaluated during longitudinal follow-up.

    Time frame: Baseline to annual follow-up through 5 years.

  23. Change From Baseline in Right Ventricular Fractional Area Change

    Right ventricular fractional area change (RV FAC) will be assessed by echocardiography as an index of right ventricular systolic function. Change from baseline will be evaluated during longitudinal follow-up.

    Time frame: Baseline to annual follow-up through 5 years.

  24. Change From Baseline in TAPSE/sPAP Ratio

    The ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/sPAP) will be calculated from echocardiographic measurements as a noninvasive marker of right ventricular-pulmonary arterial coupling. Change from baseline will be evaluated during longitudinal follow-up.

    Time frame: Baseline to annual follow-up through 5 years.

Other outcomes

  1. Predictive Performance of AI-Enabled Multimodal Models for Major Clinical Worsening

    Artificial intelligence and machine-learning approaches will be used to derive data-driven nocturnal physiological phenotypes and to develop multimodal prediction models integrating sleep-derived signals with clinical, hemodynamic, imaging, electrocardiographic, and laboratory variables. Predictive performance for the primary longitudinal outcome of major clinical worsening will be evaluated using the area under the receiver operating characteristic curve (AUROC) in held-out or center-level validation datasets.

    Time frame: From baseline assessment through 5 years of follow-up.

  2. Treatment-Response Heterogeneity According to Baseline Sleep Phenotype

    Treatment response will be evaluated according to baseline sleep-disordered breathing and nocturnal physiological phenotype. A clinically meaningful response will be defined as improvement by at least one category in the ESC/ERS four-strata PAH risk classification following initiation or escalation of PAH-targeted therapy. The proportion of participants achieving this predefined response will be compared across baseline sleep phenotypes. Analyses will account for treatment regimen, baseline disease severity, and other relevant confounders.

    Time frame: From treatment initiation or escalation to the subsequent clinical reassessment, generally within 3-12 months, and through 5 years of follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events, Version 3. Released 2023; current online scoring reference.
  • Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J. 2021 Jan 5;57(1):2002258. doi: 10.1183/13993003.02258-2020. Print 2021 Jan. PubMed 32747397 ↗
  • Spiesshoefer J, Herkenrath S, Harre K, Kahles F, Florian A, Yilmaz A, Mohr M, Naughton M, Randerath W, Emdin M, Passino C, Regmi B, Dreher M, Boentert M, Giannoni A. Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants, and Clinical Consequences. Respiration. 2021;100(9):865-876. doi: 10.1159/000515602. Epub 2021 Apr 28. PubMed 33910200 ↗
  • Nagaoka M, Goda A, Takeuchi K, Kikuchi H, Finger M, Inami T, Soejima K, Satoh T. Nocturnal Hypoxemia, But Not Sleep Apnea, Is Associated With a Poor Prognosis in Patients With Pulmonary Arterial Hypertension. Circ J. 2018 Nov 24;82(12):3076-3081. doi: 10.1253/circj.CJ-18-0636. Epub 2018 Oct 16. PubMed 30333436 ↗
  • Huang Z, Duan A, Zhao Z, Zhao Q, Zhang Y, Li X, Zhang S, Gao L, An C, Luo Q, Liu Z. Sleep-disordered breathing patterns and prognosis in pulmonary arterial hypertension: A cluster analysis of nocturnal cardiorespiratory signals. Sleep Med. 2024 Jan;113:61-69. doi: 10.1016/j.sleep.2023.11.016. Epub 2023 Nov 13. PubMed 37984019 ↗
  • Javaheri S, Somers VK. Sleep, Hypoxia, and Survival in Group 1 Pulmonary Arterial Hypertension: What to Do? J Am Coll Cardiol. 2023 Nov 21;82(21):2006-2008. doi: 10.1016/j.jacc.2023.10.005. No abstract available. PubMed 37968018 ↗
  • Lowery MM, Hill NS, Wang L, Rosenzweig EB, Bhat A, Erzurum S, Finet JE, Jellis CL, Kaur S, Kwon DH, Nawabit R, Radeva M, Beck GJ, Frantz RP, Hassoun PM, Hemnes AR, Horn EM, Leopold JA, Rischard FP, Mehra R; Pulmonary Vascular Disease Phenomics (PVDOMICS) Study Group. Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2023 Nov 21;82(21):1989-2005. doi: 10.1016/j.jacc.2023.09.806. PubMed 37968017 ↗
  • Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM; ZENITH Trial Investigators. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025 May 29;392(20):1987-2000. doi: 10.1056/NEJMoa2415160. Epub 2025 Mar 31. PubMed 40167274 ↗
  • McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Kopec G, Meyer G, Olsson KM, Fu W, Shi Y, Miller B, Kim SS, Mackenzie HS, Brambatti M, Patel MJ, Koglin J, Cornell AG, Humbert M; HYPERION Trial Investigators. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 2025 Oct 23;393(16):1599-1611. doi: 10.1056/NEJMoa2508170. Epub 2025 Sep 30. PubMed 41025556 ↗
  • Weatherald J, Fleming TR, Wilkins MR, Cascino TM, Psotka MA, Zamanian R, Seeger W, Galie N, Gomberg-Maitland M. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension. Eur Respir J. 2024 Oct 31;64(4):2401205. doi: 10.1183/13993003.01205-2024. Print 2024 Oct. PubMed 39209468 ↗
  • Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, McLaughlin VV, Sitbon O. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024 Oct 31;64(4):2401325. doi: 10.1183/13993003.01325-2024. Print 2024 Oct. PubMed 39209476 ↗
  • Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, Radegran G, Rubin LJ, Hoeper MM. Risk stratification and treatment goals in pulmonary arterial hypertension. Eur Respir J. 2024 Oct 31;64(4):2401323. doi: 10.1183/13993003.01323-2024. Print 2024 Oct. PubMed 39209472 ↗
  • Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, Badesch D, Montani D. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024 Oct 31;64(4):2401324. doi: 10.1183/13993003.01324-2024. Print 2024 Oct. PubMed 39209475 ↗
  • Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. No abstract available. PubMed 36017548 ↗

Individual participant data

Plan to share: Yes — De-identified participant-level data and a data dictionary may be shared with qualified academic investigators for scientifically sound, non-commercial research after approval by the registry Steering Committee and relevant ethics/data-governance bodies, subject to a data-use agreement and applicable Chinese regulations. Data that could enable participant re-identification will not be shared.

Supporting information: Study protocol

Time frame: Beginning after publication of the principal registry analyses and after completion of required governance review; a practical default is 12-24 months after primary publication, for a defined period specified in the approved data-use agreement.

Access criteria: Written research proposal, methodological review, investigator qualifications, ethics approval where required, data-use agreement, secure analysis environment, and commitment not to attempt re-identification or unauthorized redistribution.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2031, 62 months later.

Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 62 months is close to that.

Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 1, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2032
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852403
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
Responsible party
Zhihong Liu (Director, Chinese Pulmonary Vascular Disease Research Group) — Principal investigator
First posted
Oct 1, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 1, 2026

Study contacts

Zhihong Liu, MD, PhD
Contact
zhihongliufuwai@163.com
86-010-88398196
Zhihua Huang, MD, PhD
Contact
huangzhihua@fuwai.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion